CY1110503T1 - Πενταμιδινη για θεραπεια καρκινου - Google Patents

Πενταμιδινη για θεραπεια καρκινου

Info

Publication number
CY1110503T1
CY1110503T1 CY20091100855T CY091100855T CY1110503T1 CY 1110503 T1 CY1110503 T1 CY 1110503T1 CY 20091100855 T CY20091100855 T CY 20091100855T CY 091100855 T CY091100855 T CY 091100855T CY 1110503 T1 CY1110503 T1 CY 1110503T1
Authority
CY
Cyprus
Prior art keywords
endo
exonuclease
compounds
activity
cancer
Prior art date
Application number
CY20091100855T
Other languages
English (en)
Inventor
Terry Chow
Chiaoli Yeh
David Griller
Leonard Yuen
Original Assignee
Oncozyme Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncozyme Pharma Inc. filed Critical Oncozyme Pharma Inc.
Publication of CY1110503T1 publication Critical patent/CY1110503T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση αφορά θεραπεία καρκίνου με ενώσεις που αναστέλλουν τη δραστικότητα τη ενδο-εξωνουκλεάσης. Ενδο-εξωνουκλεάση έχει δειχθεί ότι είναι αναγκαία για την αποκατάσταση DNA που έχει υποστεί βλάβη. Ενώσεις που αναστέλλουν τη δραστικότητα ενδο-εξωνουκλεάσης έχουν δειχθεί ότι είναι ιδιαιτέρως αποτελεσματικές για θεραπεία καρκίνου όταν χρησιμοποιούνται σε συνδυασμό με φάρμακα που διεγείρουν ρήξεις DNA, όπως cis λευκόχρυσος και μιτομυκίνη C. Αυτές οι ενώσεις έχουν ένα συνεργιστικό αποτέλεσμα όταν χρησιμοποιούνται σε συνδυασμό για αναστολή ανάπτυξης όγκου. Η εφεύρεση περιλαμβάνει φαρμακευτικές συνθέσεις για αναστολή ανάπτυξης όγκου, που περιλαμβάνουν μια ένωση που αναστέλλει δραστικότητα ενδο-εξωνουκλεάσης. Αυτές οι φαρμακευτικές συνθέσεις κατά προτίμηση συμπεριλαμβάνουν ενώσεις που διεγείρουν ρήξεις DNA. Η εφεύρεση περιλαμβάνει μεθόδους θεραπείας καρκίνου με αυτές τις φαρμακευτικές συνθέσεις και χρήσεις αυτών των συνθέσεων για να θεραπεύεται καρκίνος. Οι προτιμώμενες ενώσεις που αναστέλλουν τη δραστικότητα ενδο-εξωνουκλεάσης έχουν χαμηλή τοξικότητα. Μια τέτοια ένωση είναι η πενταμιδίνη. Η εφεύρεση επίσης περιλαμβάνει μέθοδο διάγνωσης καρκίνου και παρακολούθησης της προόδου αυτού. Αυτή η άποψη της εφεύρεσης περιλαμβάνει απομόνωση ορού από έναν ασθενή, μέτρηση της συγκέντρωσης ενδο-εξωνουκλεάσης στον εν λόγω ορό και προσδιορισμό κατά πόσο η εν λόγω συγκέντρωση είναι πάνω από μια προσδιορισμένη εκ των προτέρων μέση τιμή.
CY20091100855T 1999-11-16 2009-08-11 Πενταμιδινη για θεραπεια καρκινου CY1110503T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16568899P 1999-11-16 1999-11-16
EP00975725A EP1231910B1 (en) 1999-11-16 2000-11-16 Pentamidine for treating cancer

Publications (1)

Publication Number Publication Date
CY1110503T1 true CY1110503T1 (el) 2015-04-29

Family

ID=22600019

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100855T CY1110503T1 (el) 1999-11-16 2009-08-11 Πενταμιδινη για θεραπεια καρκινου

Country Status (12)

Country Link
US (2) US20060276548A1 (el)
EP (1) EP1231910B1 (el)
JP (1) JP2003515534A (el)
AT (1) ATE431734T1 (el)
AU (1) AU780538B2 (el)
CA (1) CA2388674C (el)
CY (1) CY1110503T1 (el)
DE (1) DE60042245D1 (el)
DK (1) DK1231910T3 (el)
ES (1) ES2327313T3 (el)
PT (1) PT1231910E (el)
WO (1) WO2001035935A2 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097794A2 (en) * 2000-06-21 2001-12-27 Georgetown University Inhibitors of matriptase for the treatment of cancer
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
ITMI20021455A1 (it) * 2002-07-02 2004-01-02 Ugo Raffaello Citernesi Formulazioni fosfolipidiche di lexitropsine loro preparazione ed impiego terapeutico
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
EP1737472B1 (en) 2004-03-29 2014-08-13 University Of South Florida Effective treatment of tumors and cancer with triciribine
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
JPWO2006062072A1 (ja) * 2004-12-10 2008-08-07 テムリック株式会社 転移癌治療剤および癌転移抑制剤
WO2009086485A1 (en) 2007-12-28 2009-07-09 Server Technology, Inc. Power distribution, management, and monitoring systems and methods
RU2011142806A (ru) * 2009-05-01 2013-06-10 ОНКОЗИМ ФАРМА ИНК. (Канада) Комбинации пентамидина для лечения рака
WO2014008592A1 (en) * 2012-07-13 2014-01-16 Oncozyme Pharma Inc. Combinations comprising diamidine compounds and parp inhibitors for use iν treating cancer
CA3075664C (en) 2017-11-16 2020-12-29 Montdorex Inc. Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity
CN111671904B (zh) * 2020-04-15 2022-12-06 四川大学华西第二医院 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2145528C3 (de) * 1971-09-11 1981-12-17 Heinrich Mack Nachf., 7918 Illertissen Exonuclease und diese enthaltendes cytostatisches Mittel
EP0585957A1 (en) * 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Recombinant B-cell differentiation factor
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
DE3872635T2 (de) * 1987-04-09 1992-12-17 Fisons Plc Pentamidin enthaltende pharmazeutische zusammensetzungen.
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US4856528A (en) * 1987-06-26 1989-08-15 John Hopkins University Tumor volume determination
US5204352A (en) * 1987-09-29 1993-04-20 The United States Of America As Represented By The Secretary Of The Army Compounds exhibiting anti-parasitic activity and a method for their use
US5084480A (en) * 1987-11-06 1992-01-28 Fujisawa Usa, Inc. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
MX16687A (es) * 1988-07-07 1994-01-31 Ciba Geigy Ag Compuestos de biarilo y procedimiento para su preparacion.
US5037758A (en) * 1989-01-11 1991-08-06 Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada Enhanced production of biosurfactant through the use of a mutated B subtilis strain
GB8903438D0 (en) * 1989-02-15 1989-04-05 May & Baker Ltd New compositions of matter
US5352581A (en) * 1989-03-24 1994-10-04 United States/National Institutes Of Health Sensitive yeast genetic system for identifying agents causing double-stranded DNA damage
AU7162791A (en) * 1989-12-27 1991-07-24 Miroslav Radman Novel system for isolating and producing new genes, gene products and dna sequences
US5324830A (en) * 1991-03-26 1994-06-28 United States Of America Chimeric protein that has a human RHo Motif and deoxyribonuclease activity
US5489524A (en) * 1991-03-26 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein that has a human Rho motif and deoxyribonuclease activity
US5283238A (en) * 1992-04-24 1994-02-01 Immtech International, Inc. Methods of treating cancer using modified C-reactive protein
US5723288A (en) * 1994-05-06 1998-03-03 The University Of North Carolina At Chapel Hill Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans, and kits useful therefor
US5874283A (en) * 1995-05-30 1999-02-23 John Joseph Harrington Mammalian flap-specific endonuclease
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US5916779A (en) * 1995-09-21 1999-06-29 Becton, Dickinson And Company Strand displacement amplification of RNA targets
US5935982A (en) * 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
EP1627886A1 (en) * 1997-10-07 2006-02-22 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same, and use of them
US7115665B1 (en) * 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
AU2001240473A1 (en) * 2000-03-08 2001-09-17 Novozymes A/S Variants with altered properties
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same

Also Published As

Publication number Publication date
AU1376501A (en) 2001-05-30
EP1231910B1 (en) 2009-05-20
AU780538B2 (en) 2005-03-24
ES2327313T3 (es) 2009-10-28
PT1231910E (pt) 2009-08-06
CA2388674C (en) 2005-01-25
US20060276548A1 (en) 2006-12-07
DE60042245D1 (de) 2009-07-02
DK1231910T3 (da) 2009-08-31
ATE431734T1 (de) 2009-06-15
WO2001035935B1 (en) 2002-02-07
WO2001035935A2 (en) 2001-05-25
JP2003515534A (ja) 2003-05-07
EP1231910A2 (en) 2002-08-21
US20090068094A1 (en) 2009-03-12
CA2388674A1 (en) 2001-05-25
WO2001035935A3 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
CY1110503T1 (el) Πενταμιδινη για θεραπεια καρκινου
Xia et al. An anthocyanin-rich extract from black rice enhances atherosclerotic plaque stabilization in apolipoprotein E–deficient mice
WO2007103114A3 (en) Notch inhibition in the treatment or prevention of atherosclerosis
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
PL1889920T3 (pl) Sposób identyfikacji związków do terapii antynowotworowej in vitro
HUP0401501A2 (hu) Érrendszeri gyulladás kezelése vagy megelőzése szterin-felszívódást gátló anyagokat tartalmazó gyógyszerkészítmények alkalmazásával
ATE318606T1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
ATE550661T1 (de) Krebsdiagnose und behandlung unter verwendung eines anti-robo1-antikörper
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
ATE557087T1 (de) Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz
Akimov et al. Correction of destructive changes in connective tissues of different organs during chronic nitrate and fluoride intoxication by nanosized silica oxide
BR0311136A (pt) composto ou um sal, enanciÈmero, diaestereÈmero ou éster hidrolisável in vivo ou mistura dos mesmos farmaceuticamente aceitável, composição, e, método para inibir a atividade de fator letal (lf) liberado de bactérias em um mamìfero
Paszcuk et al. Mechanisms underlying the nociceptive and inflammatory responses induced by trypsin in the mouse paw
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
Thirumurugan Senolytic phytocompounds in redox signaling
Warenits et al. Motor cortex and hippocampus display decreased Heme oxygenase activity 2 weeks after ventricular fibrillation cardiac arrest in rats
WO2004090545A3 (en) Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative diseases
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE602004016841D1 (de) Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE69838002D1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
CONNECTIVE et al. " XVIII VV Podvysotskiy Readings